

# Recommendations for the Diagnosis and Treatment of the Acute Porphyrrias

Karl E. Anderson, MD; Joseph R. Bloomer, MD; Herbert L. Bonkovsky, MD; James P. Kushner, MD; Claus A. Pierach, MD; Neville R. Pimstone, MD; and Robert J. Desnick, PhD, MD

The acute porphyrias, 4 inherited disorders of heme biosynthesis, cause life-threatening attacks of neurovisceral symptoms that mimic many other acute medical and psychiatric conditions. Lack of clinical recognition often delays effective treatment, and inappropriate diagnostic tests may lead to misdiagnosis and inappropriate treatment. We review the clinical manifestations, pathophysiology, and genetics of the acute porphyrias and provide recommendations for diagnosis and treatment on the basis of reviews of the literature and clinical experience.

An acute porphyria should be considered in many patients with unexplained abdominal pain or other characteristic symptoms. The diagnosis can be rapidly confirmed by demonstration of a markedly increased urinary porphobilinogen level by using a single-void urine specimen. This specimen should also be saved

for quantitative measurement of porphobilinogen, 5-aminolevulinic acid, and total porphyrin levels. Intravenous hemin therapy, started as soon as possible, is the most effective treatment. Intravenous glucose alone is appropriate only for mild attacks (mild pain, no paresis or hyponatremia) or until hemin is available. Precipitating factors should be eliminated, and appropriate supportive and symptomatic therapy should be initiated. Prompt diagnosis and treatment greatly improve prognosis and may prevent development of severe or chronic neuropathic symptoms. We recommend identification of at-risk relatives through enzymatic or gene studies.

*Ann Intern Med.* 2005;142:439-450.

[www.annals.org](http://www.annals.org)

For author affiliations, see end of text.

The acute porphyrias are well-defined genetic disorders of heme biosynthesis characterized by acute life-threatening attacks of nonspecific neurologic symptoms (1). Although the specific enzyme and gene defects have been identified, diagnosis and treatment of these 4 disorders still present formidable challenges because their symptoms and signs mimic other, more common conditions. Delaying diagnosis and treatment of acute porphyric attacks can be fatal or can cause long-term or permanent neurologic damage. Updated, consistent recommendations for timely diagnosis and treatment of these disorders have been lacking, despite the existence of rapid, sensitive, and specific biochemical tests (2) and the availability of an effective therapy, which was first described more than 30 years ago (3) and was approved by the U.S. Food and Drug Administration (FDA) more than 20 years ago.

## FORMATION OF AN EXPERT PANEL AND BASIS OF RECOMMENDATIONS

Concerns about misdiagnosis, delayed diagnosis, and inappropriate therapy prompted the American Porphyria Foundation to assemble a panel of experts on the acute porphyrias who were selected on the basis of their clinical and research experience and their contributions to the medical literature. The panel, which represents specialties including internal medicine, pediatrics, genetics, gastroenterology, hepatology, and hematology, was charged with formulating updated recommendations for diagnosing and treating the acute porphyrias.

With support from the American Porphyria Foundation, the panel members convened for a day-long meeting to formulate clinical recommendations. Two members, assisted by a medical writer funded by the Foundation, pre-

pared a draft manuscript based on the panel's discussion and recommendations. All panel members participated in the review and revision of the manuscript and agreed to the final version.

Recommendations are based on the clinical experience of the authors and their review of the literature. Because the acute porphyrias are rare, most of the literature consists of reviews, small series, and case studies. A detailed MEDLINE search on treatment of acute attacks, for example, revealed 71 papers (55 in English and 16 with English abstracts) published between 1966 and October 2004. Of these, 41 were single-case reports, 13 were case series of 10 or fewer patients, and 17 (11 in English) were studies with more than 10 patients (4–20). Altogether, 53 papers discuss more than 1000 patients who received hemin therapy with or without initial treatment with glucose.

The American Porphyria Foundation partially funded this review. This nonprofit organization provides information and support to patients with porphyria and their physicians. It receives funding from private sources in addition to a nonrestricted grant from Ovation Pharmaceuticals, the manufacturer of hemin for injection (Panhematin), the only FDA-approved hemin therapy for the acute porphyrias. The Foundation and Ovation Pharmaceuticals had no

See also:

### Print

Key Summary Points . . . . . 440

### Web-Only

Conversion of figures and tables into slides

**Key Summary Points****Early Diagnosis of Acute Porphyria**

Consider in all adults with unexplained symptoms seen in acute porphyrias (Table 2); certain clinical features are suggestive: women of reproductive age; abdominal pain; muscle weakness; hyponatremia; and dark or reddish urine.

Establish diagnosis promptly by testing for increased porphobilinogen in a single-void urine (we recommend the Trace PBG Kit [Thermo Trace/DMA, Arlington, Texas]).

If porphobilinogen is increased, begin treatment immediately. To establish the type of acute porphyria, save the same urine sample for measurement of ALA, porphobilinogen, and porphyrin levels, and measure plasma porphyrin levels, fecal porphyrin levels, and erythrocyte porphobilinogen deaminase levels (Table 5 and Figure).

**Treatment of the Acute Attack**

Hospitalize patient for control of acute symptoms and withdraw all unsafe medications (see Table 3) and other possible precipitating factors.

Provide nutritional support and symptomatic and supportive treatment; consider seizure precautions, especially if patient is hyponatremic; use medications that are known to be safe in the acute porphyrias; and use intravenous fluids to correct dehydration and electrolyte imbalances, narcotic analgesics for pain, phenothiazine for nausea or vomiting, and  $\beta$ -adrenergic blockers for hypertension and symptomatic tachycardia.

Begin hemin (3 to 4 mg daily for at least 4 days) as soon as possible. Intravenous glucose alone (10%, at least 300 g daily) may resolve mild attacks (mild pain, no paresis, or hyponatremia) or can be given while awaiting delivery of hemin.

Monitor patient closely: Check vital capacity (if impaired, place patient in intensive care) and neurologic status, including muscle strength (especially proximal); check serum electrolytes, creatinine, and magnesium levels at least daily; and watch for bladder distention.

**Follow-up**

Educate patient and family about the disease, its inheritance, precipitating factors, and important preventive measures.

Encourage patients to wear medical alert bracelets and keep records of diagnostic studies and recommended therapy.

Treat chronic manifestations (such as pain and depression) and disability. Provide access to genetic testing for patient and family members.

intermediates arise from, and accumulate in, the liver or in developing erythrocytes. They are also classified clinically as acute or cutaneous on the basis of their major clinical manifestations. Of the 5 hepatic porphyrias, 4 characteristically present with acute attacks of neurologic manifestations—hence the designation *acute porphyrias*, a term that does not fully describe the clinical features, which can be prolonged and chronic.

Table 1 shows the genetic and enzymatic features of the 4 acute hepatic porphyrias (21): acute intermittent porphyria, hereditary coproporphyria, variegate porphyria, and the very rare 5-aminolevulinic acid (ALA)-dehydratase porphyria. The combined prevalence of these diseases is approximately 5 cases per 100 000 persons (1). Numerous mutations have been identified for each disorder. The major manifestations of the acute porphyrias are neurologic, including neuropathic abdominal pain, peripheral neuropathy, and mental disturbances (Table 2) (1, 4, 22–25). These develop during adult life, are more common in women than in men, and are treated by methods to restore heme homeostasis. Variegate porphyria and, much less commonly, hereditary coproporphyria can also cause chronic, blistering lesions on sun-exposed skin that are identical to those in porphyria cutanea tarda, a much more common condition. Photocutaneous lesions may occur without neuropathic manifestations.

In addition to their highly variable neurologic signs and symptoms, the acute porphyrias are distinct from other porphyrias because of their common overproduction of the porphyrin precursors ALA (an amino acid), and porphobilinogen (a pyrrole). This striking biochemical feature is important for laboratory diagnosis and has implications for pathogenesis of the neurologic manifestations. While porphyrins (tetrapyrroles) are also increased, their measurement is of little value for initial diagnosis because they are also increased (in urine, feces, erythrocytes, or plasma) in other porphyrias and many other medical conditions.

**Pathogenesis of Acute Attacks**

The enzyme deficiency in each disorder is partial (approximately 50% of normal in the 3 most common acute porphyrias), and the remaining enzyme activity is usually sufficient for heme homeostasis. Because ALA dehydratase activity normally greatly exceeds that of the other enzymes in the pathway, a more severe deficiency of this enzyme ( $\leq 5\%$  of normal) is required to cause manifestations of ALA-dehydratase porphyria. These enzymatic defects “predispose” the affected persons to the effects of precipitating factors, including many drugs (for example, barbiturates, anticonvulsants, rifampin, and progestins), endogenous steroid hormones (especially progesterone), fasting, dieting, smoking, and stress from illness, all of which can increase the demand for hepatic heme and induce synthesis of ALA synthase, the first enzyme in the heme biosynthetic pathway. Because hepatic ALA synthase is rate-controlling, production of heme pathway intermediates increases to the

role in the literature review, the formulation of recommendations, or the drafting and revising of the manuscript.

**OVERVIEW OF THE ACUTE PORPHYRIAS****Acute Porphyrias Are Inborn Errors of Heme Biosynthesis**

Each of the acute porphyrias results from the deficient activity of a distinct enzyme in the heme biosynthetic pathway (1). Porphyrias are classified as hepatic or erythroid, depending on whether most of the heme biosynthetic in-

Table 1. Characteristics of the 4 Acute Porphyrias\*

Disease (Abbreviation)	Inheritance	Deficient Enzymes (Synonyms; Sequence in Pathway)	Subcellular Locations	Enzyme Activity, % of normal	Known Mutations, nt	Gene Locus	OMIM Number†
Acute intermittent porphyria (AIP)	Autosomal dominant	PBG deaminase (HMB synthase; third)‡	Cytosolic	~50	227	11q23.3	+176000
Hereditary coproporphyrinemia (HCP)	Autosomal dominant	Coproporphyrinogen oxidase (sixth)	Mitochondrial	~50	36	3q12	+121300
Variete porphyria (VP)	Autosomal dominant	Protoporphyrinogen oxidase (seventh)	Mitochondrial	~50	120	1q22	#176200
ALA-dehydratase deficient porphyria (ADP)	Autosomal recessive	ALA dehydratase (porphobilinogen synthase; second)	Cytosolic	~5	7	9q34	+125270

\* Acute intermittent porphyria is the most prevalent and 5-aminolevulinic acid–dehydratase deficient porphyria is the least prevalent of these diseases in the United States. ALA = 5-aminolevulinic acid ( $\delta$ -aminolevulinic acid); HMB = hydroxymethylbilane; OMIM = Online Mendelian Inheritance in Man; PBG = porphobilinogen.

† Human Gene Mutation Database ([www.hgmd.org](http://www.hgmd.org)) (21) as of 14 October 2004.

‡ Online Mendelian Inheritance in Man (for additional information on disease and its genetics) ([www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=OMIM](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=OMIM)).

§ Formerly known as uroporphyrinogen I synthase.

point at which the inherited partial enzyme deficiency becomes limiting, and intermediates accumulate in the liver. Porphobilinogen and ALA levels are increased in all patients with acute symptoms of these disorders and in some who are asymptomatic.

The cause of hepatic overproduction of porphyrin precursors in the acute porphyrias is better understood than are the mechanisms for neurologic damage. Presumably, symptoms result primarily from the porphyrin precursors themselves rather than a deficiency of heme in nerve tissue (26, 27). Chronic symptoms and signs may reflect previous, unresolved neurologic damage. In the very rare cases of homozygous acute intermittent porphyria (26), variegate porphyria (28), and hereditary coproporphyrinemia (29), severe neurologic manifestations begin in childhood. An allogeneic liver transplantation in a woman with heterozygous acute intermittent porphyria normalized her urinary ALA

and porphobilinogen levels in 24 hours and completely eliminated her recurrent neurologic attacks, which supports the hepatic overproduction of porphyrin precursors in causing the neurologic symptoms (27). Similarly, a patient with variegate porphyria manifested biochemical improvement after a liver transplantation for alcoholic cirrhosis (30). However, liver transplantation was not beneficial clinically or biochemically in a child with severe ALA-dehydratase porphyria (31). These important but limited case experiences help establish the role of the hepatic overproduction of heme precursors in causing neurologic manifestations of acute porphyrias but do not yet support the broad application of liver transplantation in these disorders.

Approximately 80% of carriers of a gene mutation for acute intermittent porphyria, variegate porphyria, and hereditary coproporphyrinemia remain asymptomatic, and others

Table 2. Common Presenting Symptoms and Signs of Acute Porphyria\*

Symptoms and Signs	Estimated Incidence, %	Comment
<b>Gastrointestinal</b>		
Abdominal pain	85–95	Usually unremitting (for hours or longer) and poorly localized but can be cramping. Neurologic in origin and rarely accompanied by peritoneal signs, fever, or leukocytosis.
Vomiting	43–88	Nausea and vomiting often accompany abdominal pain.
Constipation	48–84	May be accompanied by bladder paresis.
Diarrhea	5–12	
<b>Neurologic</b>		
Pain in extremities, back, chest, neck, or head	50–70	Pain may begin in the chest or back and move to the abdomen. Extremity pain indicates involvement of sensory nerves, with objective sensory loss reported in 10%–40% of cases.
Paresis	42–68	May occur early or late during a severe attack. Muscle weakness usually begins proximally rather than distally and more often in the upper than lower extremities.
Respiratory paralysis	9–20	Preceded by progressive peripheral motor neuropathy and paresis.
Mental symptoms	40–58	May range from minor behavioral changes to agitation, confusion, hallucinations, and depression.
Convulsions	10–20	A central neurologic manifestation of porphyria or due to hyponatremia, which often results from syndrome of inappropriate antidiuretic hormone secretion or sodium depletion.
<b>Cardiovascular</b>		
Tachycardia	28, 64–85	May warrant treatment to control rate, if symptomatic (see text).
Systemic arterial hypertension	36–55	May require treatment during acute attacks, and sometimes becomes chronic.

\* Based on several series of patients with symptomatic acute intermittent porphyria (1, 4, 22–25).

**Table 3. Some Major Drugs Considered Unsafe and Safe in Acute Porphyrias\***

Unsafe	Safe
Alcohol	Acetaminophen
Barbiturates†	Aspirin
Carbamazepine†	Atropine
Carisoprodol†	Bromides
Clonazepam (high doses)	Cimetidine
Danazol†	Erythropoietin§
Diclofenac and possibly other NSAIDs†	Gabapentin
Ergots	Glucocorticoids
Estrogenst‡	Insulin
Ethchlorvynol†	Narcotic analgesics
Glutethimide†	Penicillin and derivatives
Griseofulvin†	Phenothiazines
Mephenytoin	Ranitidine†§
Meprobamate (also mebutamate and tybutamate)†	Streptomycin
Methyprylon	
Metoclopramide†	
Phenytoin†	
Primidone†	
Progesterone and synthetic progestins†	
Pyrazinamide†	
Pyrazolones (aminopyrine and antipyrine)	
Rifampin†	
Succinimides (ethosuximide and methsuximide)	
Sulfonamide antibiotics†	
Valproic acid†	

\* More extensive list of drugs and their status are available in texts (1) and Web sites (such as [www.porphyrifoundation.com](http://www.porphyrifoundation.com) and [www.porphyrria-europe.com](http://www.porphyrria-europe.com)). NSAIDs = nonsteroidal anti-inflammatory drugs.

† Porphyria is listed as a contraindication, warning, precaution, or adverse effect in U.S. labeling for these drugs. For drugs listed as unsafe, absence of such cautionary statements in U.S. labeling does not imply lower risk.

‡ Estrogens have been regarded as harmful, mostly from experience with estrogen-progestin combinations and because they can exacerbate porphyria cutanea tarda. Although evidence that they exacerbate acute porphyrias is weak, they should be used with caution. Low doses of estrogen (e.g., transdermal) have been used safely to prevent side effects of gonadotropin-releasing hormone analogues in women with cyclic attacks.

§ Although porphyria is listed as a precaution in U.S. labeling, these drugs are regarded as safe by other sources.

may have only 1 or a few acute attacks throughout life. Levels of ALA, porphobilinogen, and porphyrins in urine, serum, and feces are normal in most asymptomatic carriers of autosomal dominant acute porphyrias. Moreover, most patients with ALA-dehydratase porphyria, who may have less than 5% of normal ALA dehydratase activity, also remain asymptomatic for most of their lives.

### Common Clinical Features

Table 2 lists the most commonly reported clinical features of acute intermittent porphyria, which are identical in other acute porphyrias. Severe neuropathic abdominal pain, the most frequent symptom, is diffuse rather than localized and is often accompanied by nausea, vomiting, distention, constipation, and sometimes diarrhea. Other symptoms include insomnia (often an early symptom), heart palpitations, seizures (sometimes due to hyponatremia), restlessness, hallucinations, and other acute psychiatric symptoms. Hyponatremia may be due to hypothalamic involvement and inappropriate antidiuretic hormone secretion or excess gastrointestinal or renal sodium loss. Tachy-

cardia and systemic arterial hypertension may correlate with increased catecholamine production. Sudden death, presumably from cardiac arrhythmia, may also occur during an acute attack (32, 33).

Peripheral neuropathy, which is primarily motor, usually develops in the setting of abdominal pain and other features of a severe acute attack. Pain in the extremities and elsewhere indicates sensory nerve involvement. Paresis is usually symmetrical and begins proximally in the upper extremities, but it may be focal and may involve cranial nerves. Weakness may progress to respiratory and bulbar paralysis and death, especially with delayed diagnosis. Even advanced paralysis is reversible with appropriate treatment but may require many months of rehabilitation.

Long-term complications include chronic arterial hypertension, renal impairment (34), chronic liver damage, and hepatocellular carcinoma (35–40). Some patients experience chronic neuropathic pain, which may account for an increased risk for depression and suicide (18).

### Exacerbating Factors

Most exacerbating factors for acute porphyrias, including many drugs (Table 3), increase the demand for hepatic heme (particularly for cytochrome P450 enzymes) and induce ALA synthase. Many drugs cannot be classified as definitely harmful or safe because of insufficient information. Crash dieting (or other marked reductions in caloric or carbohydrate intake) is a common cause of attacks. Endogenous hormones, particularly progesterone, are important and may partially explain why attacks are more common in women and during the luteal phase of the menstrual cycle (41). Pregnancy is usually well-tolerated, but it increases attacks in some women. Cigarette smoking, which increases hepatic cytochrome P450 enzymes and presumably heme synthesis, is associated with more frequent attacks (42). Metabolic stress induced by infections or surgery, and possibly psychological stress, may lead to exacerbations. Attacks are usually due to the additive effects of several triggers, including some that are unknown.

### DIAGNOSTIC RECOMMENDATIONS

Accuracy and speed are paramount in the diagnosis of an acute porphyric attack because delayed treatment can result in neurologic damage and even death. Rapid exclusion of acute porphyrias also avoids delay in establishing an alternative diagnosis.

### When To Suspect an Acute Porphyric Attack

We recommend that acute porphyria be considered in any patient with symptoms that are prominent in these conditions, particularly abdominal pain, when initial clinical evaluation does not support another cause (see “Common Clinical Features” and Table 2). In our experience, acute porphyria is often seriously considered only after an expensive, time-consuming, and unproductive search for other abdominal conditions, including imaging studies and

Table 4. Methods for Detecting Increased Urinary Porphobilinogen\*

Method (Reference)	Feature	Principle of Test	Advantages	Disadvantages
Watson–Schwartz (43)	Qualitative	Separation of the PBG–Ehrlich’s reagent pigment from other substances by organic solvent extraction	Rapid; reagents readily available	Lacks sensitivity; no reference standards; requires several extraction steps; false-positive results common†; does not measure ALA level
Hoesch (45)	Qualitative	Strong acid favors detection of the PBG–Ehrlich’s pigment	Rapid; reagents readily available	Lacks sensitivity; no reference standards; false-positive results common†; does not measure ALA level
Mauzerall–Granick (44)	Quantitative	Anion and cation exchange resins separate PBG and ALA, respectively, from interfering substances, and ALA is reacted to form a pyrrole, before use of Ehrlich’s reagent	Rapid, if done routinely; specific; measures both ALA and PBG levels; disposable columns available	Somewhat complex if done occasionally
Trace PBG Kit‡ (46)	Semi-quantitative	Anion exchange resin, as in the Mauzerall–Granick method	Rapid; specific; kit available	Does not measure ALA level

\* ALA = 5-aminolevulinic acid ( $\delta$ -aminolevulinic acid); PBG = porphobilinogen.

† False-positive results are especially common with inexperience.

‡ Thermo Trace/DMA, Arlington, Texas.

sometimes unnecessary surgery. Establishing or excluding the diagnosis through rapid, simple laboratory testing for porphobilinogen levels within hours of initial hospitalization, rather than after several weeks or longer, should be the goal.

Although a single characteristic symptom may lead to a diagnosis, additional features in a patient with abdominal pain might heighten the suspicion of an acute porphyria (for example, dark or reddish urine; new-onset hypertension; hyponatremia; proximal muscle weakness; pain associated with the luteal phase of the menstrual cycle; recent use of medications known to exacerbate porphyria; or low-calorie, low-carbohydrate diets). No single sign or symptom is universal, and 5% to 10% of patients may not have the most common features, abdominal pain and tachycardia. The family history may be unrevealing because most carriers of the trait in affected families are asymptomatic. However, patients with abdominal pain or other suggestive findings and a family history of acute porphyria should be tested immediately.

Because misdiagnoses of porphyrias are so common, a clinician should not assume that a history of porphyria in the patient or in the kindred is accurate. Laboratory results that were the basis for the initial diagnosis must be reviewed. If these are not available, the patient should be retested before hemin is administered. We recommend that patients with established acute porphyria wear medical alert bracelets, carry medical alert cards, and maintain records that include diagnostic laboratory reports to inform health care providers of their condition.

Recurrent attacks in a patient with proven acute porphyria are often similar over time and are diagnosed largely on clinical grounds. Biochemical reconfirmation is not required and treatment should be initiated immediately, after

exclusion of other causes of symptoms (for example, pancreatitis and appendicitis).

### Biochemical Testing

Urinary porphobilinogen level is substantially increased (20 to 200 mg/L) in patients with acute attacks of acute intermittent porphyria, hereditary coproporphyria, and variegate porphyria. We recommend initial rapid testing for urinary porphobilinogen level to diagnose these most common acute porphyrias at or near the time of symptoms. Initial testing for a substantial increase in urinary porphobilinogen levels will miss the diagnosis of acute porphyria only in patients who are already receiving hemin, which can rapidly decrease ALA and porphobilinogen; the rare patient with ALA-dehydratase porphyria, which increases ALA but not porphobilinogen levels; and some cases of hereditary coproporphyria and variegate porphyria, because increases in ALA and porphobilinogen levels may be more transient in these conditions than in acute intermittent porphyria.

Most tests for porphobilinogen (Table 4) (43–46), a colorless pyrrole, rely on formation of a violet pigment with Ehrlich’s reagent (*p*-dimethylaminobenzaldehyde) (2). Porphobilinogen must be separated from other urinary substances, principally urobilinogen, that also react with Ehrlich’s aldehyde. The Mauzerall–Granick (44) and closely related methods are most reliable and are used for quantitative measurement of ALA and porphobilinogen levels. For rapid detection of increased porphobilinogen levels in urine, we recommend the Trace PBG Kit (Thermo Trace/DMA, Arlington, Texas), which detects porphobilinogen levels at concentrations greater than 6 mg/L and has a color chart for semi-quantitative estimation of higher levels (46).

During an acute attack of acute intermittent porphyria

**Table 5. Laboratory Findings That Differentiate Acute Intermittent Porphyrria, Hereditary Coproporphyrria, and Variegate Porphyrria\***

Disease	Erythrocyte Porphobilinogen Deaminase Levels	Urine Porphyrin Levels	Fecal Porphyrin Levels	Plasma Porphyrin Levels
Acute intermittent porphyria	Decreased by ~50% (in ~90% of cases)	Markedly increased, mostly uroporphyrin	Normal or slightly increased	Normal or slightly increased
Hereditary coproporphyrria	Normal	Markedly increased, mostly coproporphyrin	Markedly increased, mostly coproporphyrin†	Usually normal
Variegate porphyria	Normal	Markedly increased, mostly coproporphyrin	Markedly increased, mostly coproporphyrin† and protoporphyrin	Markedly increased, characteristic fluorescence peak‡

\* The findings listed are considered diagnostic for acute intermittent porphyria when porphobilinogen level is increased and for hereditary coproporphyrria and variegate porphyria even when porphobilinogen levels may have returned to normal.

† Mostly coproporphyrin III (49, 50).

‡ A simple test, which consists of fluorescence scanning of diluted plasma at neutral pH, readily differentiates variegate porphyria from other porphyrias that cause elevated plasma porphyrin levels and cutaneous photosensitivity (47). A plasma porphyrin level determination is the most sensitive porphyrin measurement for detecting variegate porphyria, including asymptomatic cases (48).

ria, urinary excretion of porphobilinogen is generally 220 to 880  $\mu\text{mol/d}$  (20 to 200 mg/d) (typical reference range, 0 to 18  $\mu\text{mol/d}$  [0 to 4 mg/d]). Excretion of ALA (in  $\mu\text{mol/d}$  [mg/d]) is approximately half this amount (reference range, 0 to 53  $\mu\text{mol/d}$  [0 to 7 mg/d]), since the molecular weight of ALA is half that of porphobilinogen. Because excretion of these porphyrin precursors is so high, differences in reference ranges between laboratories are of little consequence and collection of urine for 24 hours, which delays diagnosis, is unnecessary for the diagnosis of an acute attack. Urinary results expressed per gram of creatinine are readily compared with reference ranges for 24-hour excretion. Decreases occur with clinical improvement and are dramatic (but usually do not last long) after hemin therapy. After recovery from an attack of acute intermittent porphyria, levels of ALA and porphobilinogen generally remain increased, except immediately after hemin therapy or with prolonged latency. In hereditary coproporphyrria and variegate porphyria, ALA and porphobilinogen levels may be less markedly increased and may decrease more rapidly after an acute attack than in acute intermittent porphyria, and excretion of ALA is more often similar to that of porphobilinogen (both expressed in mg). Recognition of ALA-dehydratase porphyria requires measurement of urinary ALA and porphyrin levels, since the porphobilinogen level is not significantly increased.

We recommend that all major medical facilities provide for in-house determination of urinary porphobilinogen levels within hours of obtaining the sample, preferably by using the Trace PBG Kit, because a delay of several days in testing may lead to life-threatening delay in diagnosis. The single-void urine sample should be refrigerated or frozen without additives and shielded from light for subsequent quantitative ALA, porphobilinogen, and total porphyrin determinations (which can detect hereditary coproporphyrria or variegate porphyria when ALA and porphobilinogen levels have already decreased to normal). In patients with substantial renal dysfunction, ALA and porphobilinogen levels can be measured in serum.

If the porphobilinogen level is increased, second-line

testing (Table 5) (47–50) will determine the precise disorder of porphyrin metabolism, although treatment (which is the same regardless of the type of acute porphyria) should not be delayed pending these results. If only the ALA level is substantially increased, ALA-dehydratase porphyria and other causes of ALA-dehydratase deficiency should be differentiated before treatment (1).

### Biochemical Confirmation of the Type of Acute Porphyrria

Acute intermittent porphyria, variegate porphyria, and hereditary coproporphyrria are readily differentiated, especially when clinically active, by a group of second-line tests (Table 5) that include measurement of erythrocyte porphobilinogen deaminase activity, as well as urine, plasma, and fecal porphyrin levels, measured in samples collected before beginning hemin therapy. Together, these tests will also identify rare cases of dual porphyria (with deficiencies of 2 enzymes in the heme pathway). Marked increases in urinary and fecal total porphyrin levels and relative, rather than absolute, amounts of the individual porphyrins (separated by high-performance liquid chromatography or thin-layer chromatography) are of greatest diagnostic importance. Therefore, spot urine and fecal samples are suitable for second-line testing. Total plasma porphyrin levels are best measured fluorometrically either by acidification and solvent extraction or in diluted plasma at neutral pH (47).

We emphasize that relying on these second-line tests is not warranted for initial diagnosis of an acutely ill patient before treatment because they lack sensitivity, specificity, or both. Urinary porphyrin levels, for example, can be increased in many nonporphyric conditions. Coproporphyrin is the predominant porphyrin in normal urine, but it is also partially excreted in bile. Even minor liver dysfunction may reduce biliary and thus increase urinary coproporphyrin excretion. Therefore, increased urinary coproporphyrin does not always signify a disturbance in heme synthesis.

A substantial increase in ALA level with a normal porphobilinogen level suggests ALA-dehydratase porphyria.

However, further evaluation is needed to exclude other causes of ALA-dehydratase deficiency, particularly lead poisoning and hereditary tyrosinemia type I, which can produce symptoms similar to acute porphyria. In ALA-dehydratase porphyria and other ALA-dehydratase deficiency diseases, urinary coproporphyrin III and erythrocyte zinc protoporphyrin levels are also increased. Increased porphyrin levels seen in ALA-dehydratase porphyria and acute intermittent porphyria may result from metabolism of excess ALA in tissues other than the liver. Clinicians should confirm ALA-dehydratase porphyria by using both enzymatic and molecular methods.

### Enzymatic and DNA Testing

We recommend enzyme activity measurement and DNA testing to help confirm the type of acute porphyria and to enable identification of asymptomatic but at-risk relatives. Half-normal activity of erythrocyte porphobilinogen deaminase helps confirm a diagnosis of acute intermittent porphyria in patients with increased porphobilinogen. This assay is useful for screening family members once an index case has been identified. However, normal erythrocyte porphobilinogen deaminase activity does not exclude acute intermittent porphyria because some mutations in the porphobilinogen deaminase gene lead to a deficiency of the enzyme in the liver and other organs but not in erythrocytes (1, 25). A definitive diagnosis may also be precluded because 1) the normal range for erythrocyte porphobilinogen deaminase activity is wide (up to 3-fold) and low-normal and high-carrier values overlap; 2) the enzyme activity is much higher in younger than older erythrocytes and therefore increases when erythropoiesis is stimulated; and 3) improper processing, storing, and shipping of blood samples can decrease enzyme activities.

Assays of the enzymes deficient in hereditary coproporphyria and variegate porphyria are technically difficult and must be performed in extracts of cells with mitochondria, such as lymphocytes or cultured fibroblasts. These assays are available in many European reference laboratories but not in North America.

Once biochemical studies have determined the type of acute porphyria, DNA studies can identify the disease-causing mutation or mutations in the defective gene. This permits rapid and accurate testing of asymptomatic at-risk family members by DNA studies. (Mutation analysis for patients with acute porphyria and their family members is available at the Mount Sinai School of Medicine, Department of Human Genetics, New York, New York. Contact Dr. Kenneth Astrin [kenneth.astrin@mssm.edu] for information.) Most mutations are family-specific, with a few notable exceptions, including variegate porphyria in South Africa (51) and acute intermittent porphyria in northern Sweden (52), where particular mutations have been transmitted over generations from single founders.

Patients with porphyria should have genetic counseling and should be encouraged to inform family members

about the disease and its genetics. Knowledge of genetic status enables family members to make informed decisions about lifestyle and to know the potential risks of certain drugs, preferably before the development of an acute illness. However, latent porphyria should not be construed as a health risk that limits health or life insurance. Acute porphyria may be diagnosed prenatally with enzymatic and molecular studies, but this is seldom indicated because the outlook for most carriers is favorable.

### THERAPEUTIC RECOMMENDATIONS

Acute attacks require treatment of symptoms and complications and disease-specific therapy (that is, intravenous hemin) to reconstitute heme homeostasis (see Key Summary Points and Figure).


#### Supportive and Symptomatic Treatment

Hospitalization may be required for evaluating and treating severe pain, nausea, and vomiting; for administering intravenous fluids, electrolytes, glucose, and hemin; and for closely observing electrolyte derangements and neurologic complications. Medications taken by the patient should be reviewed immediately, and those identified as harmful should be stopped if possible. Narcotic analgesic drugs are usually required for abdominal pain, and small to moderate doses of a phenothiazine are indicated for nausea, vomiting, anxiety, and restlessness. The Key Summary Points contain other management considerations.

Early case studies suggested that oral or intravenous carbohydrate loading may benefit some patients (53, 54). Carbohydrate loading provides nutritional replacement, has some repressive effect on hepatic ALA synthase (55, 56), and has been a standard treatment for acute attacks for many decades. While less effective and specific than hemin, carbohydrate loading may suffice for mild attacks in patients with low narcotic requirements and without hyponatremia or paresis. Sucrose, glucose polymers, or carbohydrate-rich foods may be given to patients without abdominal distention or ileus and who can tolerate oral treatment. The standard intravenous regimen is 10% glucose for a total of at least 300 g daily. Amounts up to 500 g daily may be more effective (57). However, large volumes of 10% glucose may increase risk for hyponatremia. Severe or prolonged attacks should be treated with hemin and may also require more thorough nutrition support.

Tachycardia and systemic arterial hypertension may be treated cautiously with  $\beta$ -adrenergic blocking agents, but they may be hazardous in patients with hypovolemia, in whom increased catecholamine secretion may be an important compensatory mechanism. Seizures are difficult to treat because almost all antiseizure drugs can exacerbate an attack. Gabapentin, and probably vigabatrin, can be given safely and benzodiazepines are relatively safe. Careful correction of hyponatremia and hypomagnesemia is impor-

Figure. Recommended laboratory evaluation of patients with concurrent symptoms suggesting an acute porphyria, indicating how the diagnosis is established or excluded by biochemical testing and when specific therapy should be initiated.



This schema is not applicable to patients who have recently been treated with hemin or who have recovered from past symptoms suggestive of porphyria. Levels of 5-aminolevulinic acid (ALA) and porphobilinogen may be less increased in hereditary coproporphyria (HCP) and variegate porphyria (VP) and decrease more quickly with recovery than in acute intermittent porphyria (AIP). Mutation detection provides confirmation and greatly facilitates detection of relatives with latent porphyria. CPO = coproporphyrinogen oxidase; PBG = porphobilinogen; PPO = protoporphyrinogen oxidase.

tant, particularly when those conditions are associated with seizures.

### Hemin Therapy

Intravenous hemin addresses the underlying pathophysiology by repressing hepatic ALA synthase activity, hence decreasing the overproduction of ALA and porphobilinogen. Hemin given intravenously at moderate dosage (3 to 4 mg/kg of body weight per day) is mostly taken up in the liver and can at least transiently replenish the depleted heme pool that regulates the synthesis of ALA synthase. It cannot be given orally because it is catabolized by heme oxygenase during intestinal absorption.

Many uncontrolled clinical studies suggest a favorable biochemical and clinical response to hemin (5–8, 10, 13, 16, 17, 19, 58–60). In the only double-blind, placebo-controlled trial of hemin therapy, investigators randomly assigned 12 patients with acute porphyria to receive either hemin (as heme arginate) or placebo (12). The 9 patients who were readmitted with a subsequent attack received the therapy that they did not get during the earlier attack. This study found striking decreases in urinary porphobilinogen excretion and trends in clinical benefit (less pain, decreased need for pain medication, and shorter hospital stay) associated with hemin. However, notably, the study lacked

statistical power, treatment was delayed for 2 days in all cases, clinical assessments were limited, and information on what precipitated the attack (which could affect the likelihood of spontaneous remission in either group) was not recorded (18, 61, 62). In a larger, uncontrolled study of 22 patients and 51 acute attacks treated with heme arginate, treatment was initiated within 24 hours of admission in 37 attacks (73%). All patients responded (including 2 patients with paresis), and hospitalization was less than 7 days in 90% of cases (16). In general, early initiation of intravenous heme is associated with improved outcome (10, 16, 17, 59), and heme is more effective than glucose in reducing excretion of porphyrin precursors (3, 6, 7).

Heme therapy should be started early for most acute attacks (16, 59, 63–66). Although product labeling recommends an initial trial of intravenous glucose, heme is the preferred therapy (16, 59, 63–66). Glucose is clearly less effective and is recommended only for attacks with mild pain and no paresis. The standard regimen for heme therapy is 3 to 4 mg/kg infused intravenously once daily for 4 days. Heme (Panhematin, Ovation Pharmaceuticals, Deerfield, Illinois) is available in the United States as lyophilized hydroxyheme (hemin) for reconstitution with sterile water just before infusion and is approved by the FDA for ameliorating acute porphyric attacks. A standard 4-day treatment course costs approximately \$8000. Another heme preparation, heme arginate, is more stable in solution but is not available in the United States. We recommend that lyophilized heme be reconstituted with human albumin to enhance stability (60). Degradation products form rapidly *in vitro* when lyophilized heme is reconstituted with sterile water, as recommended in product labeling. These degradation products adhere to endothelial cells, platelets, and coagulation factors and cause a transient anticoagulant effect and often phlebitis at the site of infusion (67–71). Phlebitis can be severe and can compromise venous access with repeated administration. In our experience, reconstitution with albumin enhances stability of lyophilized heme, decreases the incidence of phlebitis, prevents the anticoagulant effect, and may enhance efficacy (60), although it increases the cost of treatment. Other uncommon reported side effects of heme include fever, aching, malaise, hemolysis, 1 case of circulatory collapse that resulted in full recovery after subsequent heme infusions (72), and 1 case of transitory renal failure after a dose of 1000 mg (73). Experience indicates that heme can be administered safely during pregnancy.

Patients should be monitored closely during therapy for complications and signs of progression of acute porphyria, such as electrolyte imbalance, acute psychiatric manifestations, muscle weakness, bladder retention, and ileus. Spirometry is sometimes indicated daily to detect respiratory impairment, at least until the attack begins to resolve. Since patients with respiratory impairment can deteriorate rapidly, we recommend that they be placed in intensive care. Levels of ALA and porphobilinogen usually decrease

to normal whether therapy is started early or late, but this does not necessarily predict a clinical response.

Clinical improvement is rapid, often within 1 to 2 days, when heme therapy is started early in an attack. Patients may be discharged from the hospital within several days, although we recommend completion of the standard 4-day treatment course in the outpatient clinic. But when treatment is delayed, neuronal damage may be advanced and slow to recover. Therefore, efficacy of heme may not be immediately apparent, and treatment for longer than 4 days should be considered, although evidence that this improves outcome is lacking. Even when severe neuropathy is arrested by treatment, complete recovery may take months or longer. Heme is seldom effective for chronic symptoms that persist between attacks. Heme therapy can be given in outpatient settings or in the home if this facilitates prompt therapy and reduces medical care costs in patients with frequent attacks.

## RECOMMENDATIONS FOR PREVENTION AND FOLLOW-UP

Prevention of future attacks requires patient education and identification of precipitating factors. Avoiding alcohol, smoking, and drugs that can induce exacerbations and maintaining adequate nutrition (Table 3) are important. Medical alert bracelets and wallet cards can help notify emergency medical personnel and ensure that unsafe drugs are not given to patients in emergencies. Some patients have frequent attacks even after exacerbating factors are removed, possibly because of unidentified modifier genes or environmental or endogenous precipitating factors. These patients should be evaluated by a nutritionist and should follow a well-balanced diet with sufficient calories to maintain weight.

Gonadotropin-releasing hormone analogues can be highly effective for women with frequent cyclic attacks when symptoms are confined to the luteal phase of the menstrual cycle (41). Unless patients have other medical indications for oophorectomy, a trial of a gonadotropin-releasing hormone analogue is preferred because it is reversible. Therapy should be started during the first few days of a cycle, and if attacks are prevented for several months, estrogen, added back in the form of a low-dose estrogen patch, can prevent menopausal symptoms. We recommend gynecologic examination and bone density determinations every 6 months during treatment. Continued need can be assessed every 1 to 2 years by stopping treatment.

Pregnancy increases levels of progesterone, a potent inducer of heme biosynthesis in liver, but nevertheless is well tolerated in most women with acute porphyria. For example, in a large series of women with acute intermittent porphyria or variegate porphyria who had 176 deliveries, porphyric symptoms were absent in 92% of these pregnancies (74). Because some women experience more frequent

attacks during pregnancy, counseling women who wish to become pregnant must be individualized. Worsening symptoms during pregnancy are sometimes due to harmful drugs (for example, metoclopramide) (75, 76), inadequate nutrition, or both.

Recurrent noncyclic attacks are sometimes prevented by weekly or biweekly infusions of hemin (77). Frequent treatment with hemin has a theoretical risk for iron overload (100 mg of hemin contains 8 mg of iron). Therefore, serum ferritin levels should be monitored. In selected, rare instances of severe, unremitting symptomatic disease, orthotopic liver transplantation may be considered (28). Transplantation of hepatocytes or specific gene replacement therapy are possible future therapeutic strategies.

End-stage renal disease may partly result from chronic systemic arterial hypertension (34) and may be delayed by effective blood pressure control. Several retrospective population-based studies in Scandinavia have found 60- to 70-fold increases in incidence of or mortality due to hepatocellular carcinoma among patients with acute porphyria as compared with national age- and sex-matched rates (36–38, 40). In addition, a prospective cohort study of 650 patients with acute porphyria followed for 7 years in France found 7 cases of hepatocellular carcinoma versus an expected 0.2 case as determined by national age- and sex-specific incidences of primary liver cancer (39). Thus, as with other conditions that predispose to liver cancer, periodic monitoring of serum  $\alpha$ -fetoprotein levels and hepatic imaging seems appropriate. Chronic depression and risk for suicide (18) are important to recognize in patients with frequent attacks or chronic symptoms and should prompt early psychiatric and effective pain management.

## IMPROVING PROGNOSIS

Reported fatality rates from acute attacks of porphyria ranged from 10% to 52% before 1970 (4, 78). Improved prognosis since 1970 may be attributed to better diagnosis, treatment, and prevention; availability of hemin (introduced in 1971); identification of at-risk gene carriers; and decreased use of harmful drugs, such as barbiturates and sulfonamide antibiotics. In a more recent U.S. study, 12 of 86 patients (14%) who received a diagnosis after 1971 died after hospitalization for acute attacks. Eleven of these patients received hemin but only after their attack had progressed to an advanced stage, with 10 patients requiring mechanical ventilation (18). Studies have estimated mortality in patients who have experienced attacks of acute porphyria to be 3-fold higher than the general population, with most deaths occurring during acute attacks (18) and delayed diagnosis and treatment still often contributing (18, 74). The Key Summary Points are intended to increase awareness of these disorders, encourage earlier and more accurate diagnosis, and suggest the earlier institution of specific therapy, with the aim of further enhancing prognosis of patients with these inherited conditions.

From the University of Texas Medical Branch, Galveston, Texas; University of Alabama at Birmingham, Birmingham, Alabama; University of Connecticut Health Center, Farmington, Connecticut; University of Utah School of Medicine, Salt Lake City, Utah; University of Minnesota School of Medicine, Minneapolis, Minnesota; University of California Davis Medical Center, Sacramento, California; Mount Sinai School of Medicine of New York University, New York, New York.

**Acknowledgments:** The authors thank Desiree Lyon Howe, Executive Director of the American Porphyria Foundation, for her support of the manuscript, and Lisa Underhill for writing assistance.

**Grant Support:** This review was supported in part by the American Porphyria Foundation, by grants to Dr. Anderson from the U.S. Food and Drug Administration (FD-R-00-1459) and a grant to the University of Texas Medical Branch General Clinical Research Center from the National Center for Research Resources (M01-RR0073); by grants and contracts to Dr. Bonkovsky from the National Institutes of Health (including R01 DK38825, N01DK92326, and U01-DK065193, and M01-RR06192 to the University of Connecticut General Clinical Research Center); and by grants to Dr. Desnick from the National Institutes of Health (including a research grant (5 R01 DK26824) and a grant (2 M01 RR00071) to the Mount Sinai General Clinical Research Center from the National Center for Research Resources).

**Potential Financial Conflicts of Interest:** *Grants pending:* K.E. Anderson (Ovation Pharmaceuticals); *Grants received:* J.R. Bloomer (Ovation Pharmaceuticals).

**Requests for Single Reprints:** Robert J. Desnick, PhD, MD, Department of Human Genetics, Mount Sinai School of Medicine, Box 1498, Fifth Avenue at 100th Street, New York, NY 10029; e-mail, rjdesnick@mssm.edu.

Current author addresses are available at [www.annals.org](http://www.annals.org).

## References

- Anderson K, Sassa S, Bishop D, Desnick R. Disorders of heme biosynthesis: X-linked sideroblastic anemia and the porphyrias. In: Scriver C, Beaudet A, Sly W, Valle D, Childs B, Kinzler K, Vogelstein B, eds. *Metabolic and Molecular Bases of Inherited Disease*. New York: McGraw-Hill; 2001:2991-3062.
- Bonkovsky HL, Barnard GF. Diagnosis of porphyric syndromes: a practical approach in the era of molecular biology. *Semin Liver Dis*. 1998;18:57-65. [PMID: 9516679]
- Bonkovsky HL, Tschudy DP, Collins A, Doherty J, Bossenmaier I, Cardinal R, et al. Repression of the overproduction of porphyrin precursors in acute intermittent porphyria by intravenous infusions of hematin. *Proc Natl Acad Sci U S A*. 1971;68:2725-9. [PMID: 5288250]
- Stein JA, Tschudy DP. Acute intermittent porphyria. A clinical and biochemical study of 46 patients. *Medicine (Baltimore)*. 1970;49:1-16. [PMID: 4907358]
- Watson CJ, Pierach CA, Bossenmaier I, Cardinal R. Postulated deficiency of hepatic heme and repair by hematin infusions in the "inducible" hepatic porphyrias. *Proc Natl Acad Sci U S A*. 1977;74:2118-20. [PMID: 266732]
- Watson CJ, Pierach CA, Bossenmaier I, Cardinal R. Use of hematin in the acute attack of the "inducible" hepatic porphyrias. *Adv Intern Med*. 1978;23:265-86. [PMID: 343541]
- Lamon JM, Frykholm BC, Hess RA, Tschudy DP. Hematin therapy for acute porphyria. *Medicine (Baltimore)*. 1979;58:252-69. [PMID: 449661]
- Pierach CA, Bossenmaier I, Cardinal R, Weimer M, Watson CJ. Hematin therapy in porphyric attacks. *Klin Wochenschr*. 1980;58:829-32. [PMID: 7453089]
- Doss M, Verspohl F. The "glucose effect" in acute hepatic porphyrias and in

- experimental porphyria. *Klin Wochenschr.* 1981;59:727-35. [PMID: 7253546]
10. Pierach CA. Hematin therapy for the porphyric attack. *Semin Liver Dis.* 1982;2:125-31. [PMID: 6753162]
  11. Doss M, Sixel-Dietrich F, Verspohl F. "Glucose effect" and rate limiting function of uroporphyrinogen synthase on porphyrin metabolism in hepatocyte culture: relationship with human acute hepatic porphyrias. *J Clin Chem Clin Biochem.* 1985;23:505-13. [PMID: 4067519]
  12. Herrick AL, McColl KE, Moore MR, Cook A, Goldberg A. Controlled trial of haem arginate in acute hepatic porphyria. *Lancet.* 1989;1:1295-7. [PMID: 2566827]
  13. Kostrzewska E, Gregor A, Tarczyńska-Nosal S. Heme arginate (Normosang) in the treatment of attacks of acute hepatic porphyrias. *Mater Med Pol.* 1991;23:259-62. [PMID: 1842231]
  14. Armas R, Wolff C, Krause P, Chaná P, Parraguez A, Soto J. [The hepatic porphyrias: experience with 105 cases]. *Rev Med Chil.* 1992;120:259-66. [PMID: 1342477]
  15. Kostrzewska E, Gregor A, Tarzhinska-Nosal S. [Organization and results of studies on acute hepatic porphyrias in Poland]. *Gematol Transfuziol.* 1992;37:3-4. [PMID: 1295780]
  16. Mustajoki P, Nordmann Y. Early administration of heme arginate for acute porphyric attacks. *Arch Intern Med.* 1993;153:2004-8. [PMID: 8357285]
  17. Nordmann Y, Deybach JC. [Acute attacks of hepatic porphyria: specific treatment with heme arginate]. *Ann Med Interne (Paris).* 1993;144:165-7. [PMID: 8368699]
  18. Jeans JB, Savik K, Gross CR, Weimer MK, Bossenmaier IC, Pierach CA, et al. Mortality in patients with acute intermittent porphyria requiring hospitalization: a United States case series. *Am J Med Genet.* 1996;65:269-73. [PMID: 8923933]
  19. Kostrzewska E, Gregor A. Acute hepatic porphyrias. Detection, prophylaxis and treatment. *Mater Med Pol.* 1996;28:5-7. [PMID: 9088118]
  20. Morales Ortega X, Wolff Fernández C, Leal Ibarra T, Montaña Navarro N, Armas-Merino R. [Porphyric crisis: experience of 30 episodes]. *Medicina (B Aires).* 1999;59:23-7. [PMID: 10349114]
  21. Stenson PD, Ball EV, Mort M, Phillips AD, Shiel JA, Thomas NS, et al. Human Gene Mutation Database (HGMD): 2003 update. *Hum Mutat.* 2003;21:577-81. [PMID: 12754702]
  22. Waldenstrom J. The porphyrias as inborn errors of metabolism. *Am J Med.* 1957;22:758-73. [PMID: 13410965]
  23. Goldberg A. Acute intermittent porphyria: a study of 50 cases. *Q J Med.* 1959;28:183-209. [PMID: 13658350]
  24. Mustajoki P, Koskelo P. Hereditary hepatic porphyrias in Finland. *Acta Med Scand.* 1976;200:171-8. [PMID: 970225]
  25. Nordmann Y, Puy H. Human hereditary hepatic porphyrias. *Clin Chim Acta.* 2002;325:17-37. [PMID: 12367763]
  26. Solis C, Martinez-Bermejo A, Naidich TP, Kaufmann WE, Astrin KH, Bishop DF, et al. Acute intermittent porphyria: studies of the severe homozygous dominant disease provides insights into the neurologic attacks in acute porphyrias. *Arch Neurol.* 2004;61:1764-70. [PMID: 15534187]
  27. Soonawalla ZF, Orug T, Badminton MN, Elder GH, Rhodes JM, Bramhall SR, et al. Liver transplantation as a cure for acute intermittent porphyria. *Lancet.* 2004;363:705-6. [PMID: 15001330]
  28. Hift RJ, Meissner PN, Todd G, Kirby P, Bilsland D, Collins P, et al. Homozygous variegate porphyria: an evolving clinical syndrome. *Postgrad Med J.* 1993;69:781-6. [PMID: 8290408]
  29. Nordmann Y, Grandchamp B, de Verneuil H, Phung L, Cartigny B, Fontaine G. Harderoporphyria: a variant hereditary coproporphyrin. *J Clin Invest.* 1983;72:1139-49. [PMID: 6886003]
  30. Stojeba N, Meyer C, Jeanpierre C, Perrot F, Hirth C, Pottecher T, et al. Recovery from a variegate porphyria by a liver transplantation. *Liver Transpl.* 2004;10:935-8. [PMID: 15237381]
  31. Thunell S, Henrichson A, Floderus Y, Groth CG, Eriksson BG, Barkholt L, et al. Liver transplantation in a boy with acute porphyria due to aminolaevulinatase deficiency. *Eur J Clin Chem Clin Biochem.* 1992;30:599-606. [PMID: 1493152]
  32. Ridley A. Porphyric neuropathy. In: Dyck PJ, Thomas PK, Lambert EH, eds. *Peripheral Neuropathy.* vol. 2. Philadelphia: WB Saunders; 1975:942-55.
  33. Stein JA, Curl FD, Valsamis M, Tschudy DP. Abnormal iron and water metabolism in acute intermittent porphyria with new morphologic findings. *Am J Med.* 1972;53:784-9. [PMID: 4634732]
  34. Church SE, McColl KE, Moore MR, Youngs GR. Hypertension and renal impairment as complications of acute porphyria. *Nephrol Dial Transplant.* 1992;7:986-90. [PMID: 1331893]
  35. Ostrowski J, Kostrzewska E, Michalak T, Zawirska B, Medrzejewski W, Gregor A. Abnormalities in liver function and morphology and impaired aminopyrine metabolism in hereditary hepatic porphyrias. *Gastroenterology.* 1983;85:1131-7. [PMID: 6618105]
  36. Lithner F, Wetterberg L. Hepatocellular carcinoma in patients with acute intermittent porphyria. *Acta Med Scand.* 1984;215:271-4. [PMID: 6328897]
  37. Kauppinen R, Mustajoki P. Acute hepatic porphyria and hepatocellular carcinoma. *Br J Cancer.* 1988;57:117-20. [PMID: 2831925]
  38. Andersson C, Bjersing L, Lithner F. The epidemiology of hepatocellular carcinoma in patients with acute intermittent porphyria. *J Intern Med.* 1996;240:195-201. [PMID: 8918510]
  39. Andant C, Puy H, Faivre J, Deybach JC. Acute hepatic porphyrias and primary liver cancer [Letter]. *N Engl J Med.* 1998;338:1853-4. [PMID: 9634374]
  40. Linet MS, Gridley G, Nyrén O, Mellemljaer L, Olsen JH, Keehn S, et al. Primary liver cancer, other malignancies, and mortality risks following porphyria: a cohort study in Denmark and Sweden. *Am J Epidemiol.* 1999;149:1010-5. [PMID: 10355376]
  41. Anderson KE, Spitz IM, Bardin CW, Kappas A. A gonadotropin releasing hormone analogue prevents cyclical attacks of porphyria. *Arch Intern Med.* 1990;150:1469-74. [PMID: 2196028]
  42. Lip GY, McColl KE, Goldberg A, Moore MR. Smoking and recurrent attacks of acute intermittent porphyria. *BMJ.* 1991;302:507. [PMID: 2012848]
  43. Watson CJ, Schwartz S. A simple test for urinary porphobilinogen. *Proc Soc Exp Biol Med.* 1941;47:393-4.
  44. Mauzerall D, Granick S. The occurrence and determination of delta-aminolevulinic acid and porphobilinogen in urine. *J Biol Chem.* 1956;219:435-46. [PMID: 13295297]
  45. Lamon J, With TK, Redeker AG. The Hoesch test: bedside screening for urinary porphobilinogen in patients with suspected porphyria. *Clin Chem.* 1974;20:1438-40. [PMID: 4425514]
  46. Deacon AC, Peters TJ. Identification of acute porphyria: evaluation of a commercial screening test for urinary porphobilinogen. *Ann Clin Biochem.* 1998;35 (Pt 6):726-32. [PMID: 9838985]
  47. Poh-Fitzpatrick MB. A plasma porphyrin fluorescence marker for variegate porphyria. *Arch Dermatol.* 1980;116:543-7. [PMID: 7377785]
  48. Hift RJ, Davidson BP, van der Hooff C, Meissner DM, Meissner PN. Plasma fluorescence scanning and fecal porphyrin analysis for the diagnosis of variegate porphyria: precise determination of sensitivity and specificity with detection of protoporphyrinogen oxidase mutations as a reference standard. *Clin Chem.* 2004;50:915-23. [PMID: 14976149]
  49. Blake D, McManus J, Cronin V, Ratnaik S. Fecal coproporphyrin isomers in hereditary coproporphyrin. *Clin Chem.* 1992;38:96-100. [PMID: 1733615]
  50. Jacob K, Doss MO. Excretion pattern of faecal coproporphyrin isomers I-IV in human porphyrias. *Eur J Clin Chem Clin Biochem.* 1995;33:893-901. [PMID: 8845420]
  51. Meissner PN, Dailey TA, Hift RJ, Ziman M, Corrigan AV, Roberts AG, et al. A R59W mutation in human protoporphyrinogen oxidase results in decreased enzyme activity and is prevalent in South Africans with variegate porphyria. *Nat Genet.* 1996;13:95-7. [PMID: 8673113]
  52. Lee JS, Anvret M. Identification of the most common mutation within the porphobilinogen deaminase gene in Swedish patients with acute intermittent porphyria. *Proc Natl Acad Sci U S A.* 1991;88:10912-5. [PMID: 1961762]
  53. Welland FH, Hellman ES, Gaddis EM, Collins G, Hunter GW Jr, Tschudy DP. Factors affecting the excretion of porphyrin precursors by patients with acute intermittent porphyria. I. The effect of diet. *Metabolism.* 1964;13:232-50. [PMID: 14127691]
  54. Felsher BF, Redeker AG. Acute intermittent porphyria: effect of diet and griseofulvin. *Medicine (Baltimore).* 1967;46:217-23. [PMID: 6027463]
  55. Rose JA, Hellman ES, Tschudy DP. Effect of diet on induction of experimental porphyria. *Metabolism.* 1961;10:514-21. [PMID: 13743276]

56. Tschudy DP, Welland FH, Collins A, Hunter G Jr. The effect of carbohydrate feeding on the induction of delta-aminolevulinic acid synthetase. *Metabolism*. 1964;13:396-406. [PMID: 14169218]
57. Tschudy DP, Valsamis M, Magnussen CR. Acute intermittent porphyria: clinical and selected research aspects. *Ann Intern Med*. 1975;83:851-64. [PMID: 1106284]
58. McColl KE, Moore MR, Thompson GG, Goldberg A. Treatment with haematin in acute hepatic porphyria. *Q J Med*. 1981;50:161-74. [PMID: 7302116]
59. Mustajoki P, Tenhunen R, Tokola O, Gothoni G. Haem arginate in the treatment of acute hepatic porphyrias. *Br Med J (Clin Res Ed)*. 1986;293:538-9. [PMID: 3092906]
60. Bonkovsky HL, Healey JF, Lourie AN, Gerron GG. Intravenous heme-albumin in acute intermittent porphyria: evidence for repletion of hepatic hemo-proteins and regulatory heme pools. *Am J Gastroenterol*. 1991;86:1050-6. [PMID: 1713408]
61. Pierach CA. Haem and porphyria attacks [Letter]. *Lancet*. 1989;2:213-4. [PMID: 2568536]
62. Tenhunen R, Mustajoki P. Acute porphyria: treatment with heme. *Semin Liver Dis*. 1998;18:53-5. [PMID: 9516678]
63. Elder GH, Hift RJ, Meissner PN. The acute porphyrias. *Lancet*. 1997;349:1613-7. [PMID: 9174571]
64. Thadani H, Deacon A, Peters T. Diagnosis and management of porphyria. *BMJ*. 2000;320:1647-51. [PMID: 10856069]
65. Anderson KE. Approaches to treatment and prevention of human porphyrias. In: Kadish K, Smith K, Guillard R, eds. *The Porphyrin Handbook. Medical Aspects of Porphyrins*. vol. 14. San Diego, CA: Academic Pr, Elsevier Science; 2003:247-83.
66. Wilson J, de Rooij F. Management and treatment of the porphyrias. In: Kadish KM, Smith KM, Guillard R, eds. *Porphyrin Handbook. Medical Aspects of Porphyrins*. vol. 14. San Diego: Academic Pr; 2003:285-302.
67. Green D, Reynolds N, Klein J, Kohl H, Ts'ao CH. The inactivation of hemostatic factors by hematin. *J Lab Clin Med*. 1983;102:361-9. [PMID: 6411843]
68. Goetsch CA, Bissell DM. Instability of hematin used in the treatment of acute hepatic porphyria. *N Engl J Med*. 1986;315:235-8. [PMID: 3724815]
69. Green D, Furby FH, Berndt MC. The interaction of the factor VIII/von Willebrand factor complex with hematin. *Thromb Haemost*. 1986;56:277-82. [PMID: 3105105]
70. Jones RL. Hematin-derived anticoagulant. Generation in vitro and in vivo. *J Exp Med*. 1986;163:724-39. [PMID: 3950544]
71. Green D, Ts'ao CH. Hematin: effects on hemostasis. *J Lab Clin Med*. 1990;115:144-7. [PMID: 2405084]
72. Khanderia U. Circulatory collapse associated with hemin therapy for acute intermittent porphyria. *Clin Pharm*. 1986;5:690-2. [PMID: 3742954]
73. Dhar GJ, Bossenmaier I, Cardinal R, Petryka ZJ, Watson CJ. Transitory renal failure following rapid administration of a relatively large amount of hematin in a patient with acute intermittent porphyria in clinical remission. *Acta Med Scand*. 1978;203:437-43. [PMID: 665312]
74. Kauppinen R, Mustajoki P. Prognosis of acute porphyria: occurrence of acute attacks, precipitating factors, and associated diseases. *Medicine (Baltimore)*. 1992;71:1-13. [PMID: 1549056]
75. Milo R, Neuman M, Klein C, Caspi E, Arlazoroff A. Acute intermittent porphyria in pregnancy. *Obstet Gynecol*. 1989;73:450-2. [PMID: 2915870]
76. Shenhav S, Gemer O, Sassoan E, Segal S. Acute intermittent porphyria precipitated by hyperemesis and metoclopramide treatment in pregnancy. *Acta Obstet Gynecol Scand*. 1997;76:484-5. [PMID: 9197454]
77. Lamon JM, Frykholm BC, Bennett M, Tschudy DP. Prevention of acute porphyric attacks by intravenous haematin. *Lancet*. 1978;2:492-4. [PMID: 79864]
78. Kostrzewska E, Gregor A. [35 Years of effort to improve the diagnosis of porphyria]. *Przegl Lek*. 1999;56:576-8. [PMID: 10695362]

---

**Current Author Addresses:** Dr. Anderson: Departments of Preventative Medicine and Community Health, Internal Medicine, and Pharmacology and Toxicology, University of Texas Medical Branch, 700 Harbor-side Drive, Galveston, TX 77555.

Dr. Bloomer: Departments of Medicine and Genetics, University of Alabama at Birmingham, 395 BSHS, 1918 University Boulevard, Birmingham, AL 35294.

Dr. Bonkovsky: Departments of Medicine and Molecular, Microbial, and Structural Biology, University of Connecticut Health Center, 263 Farmington Avenue, Farmington, CT 06030.

Dr. Kushner: Department of Medicine, University of Utah School of

Medicine, 30 North 1900 East Room, 4C416, Salt Lake City, UT 84132.

Dr. Pierach: Department of Medicine, Abbott Northwestern Hospital, University of Minnesota School of Medicine, 800 East 28th Street, Minneapolis, MN 55407.

Dr. Pimstone: Department of Internal Medicine, University of California Davis Medical Center, 4150 V Street, Suite 3500, Sacramento, CA 95817.

Dr. Desnick: Department of Human Genetics, Mount Sinai School of Medicine, Box 1498, Fifth Avenue at 100th Street, New York, NY 10029.

**Panhematin®**  
**Hemin For Injection**


**Rx only**  
**For intravenous infusion only.**

PANHEMATIN (hemin for injection) should only be used by physicians experienced in the management of porphyrias in hospitals where the recommended clinical and laboratory diagnostic and monitoring techniques are available.

PANHEMATIN therapy should be considered after an appropriate period of alternate therapy (i.e., 400 g glucose/day for 1 to 2 days). (See "WARNINGS", "PRECAUTIONS" and "DOSAGE AND ADMINISTRATION" sections.)

**DESCRIPTION**

PANHEMATIN (hemin for injection) is an enzyme inhibitor derived from processed red blood cells. Hemin for injection was known previously as hematin. The term hematin has been used to describe the chemical reaction product of hemin and sodium carbonate solution. Hemin is an iron containing metalloporphyrin. Chemically hemin is represented as chloro [7,12-diethenyl-3,8,13,17-tetramethyl-21H,23H-porphine-2,18-dipropanoato(2-)-N<sup>21</sup>,N<sup>22</sup>,N<sup>23</sup>,N<sup>24</sup>] iron. The structural formula for hemin is:



PANHEMATIN is a sterile, lyophilized powder suitable for intravenous administration after reconstitution. Each dispensing vial of PANHEMATIN contains the equivalent of 313 mg hemin, 215 mg sodium carbonate and 300 mg of sorbitol. The pH may have been adjusted with hydrochloric acid; the product contains no preservatives. When mixed as directed with Sterile Water for Injection, USP, each 43 mL provides the equivalent of approximately 301 mg hematin (7 mg/mL).

**CLINICAL PHARMACOLOGY**

Heme acts to limit the hepatic and/or marrow synthesis of porphyrin. This action is likely due to the inhibition of  $\delta$ -aminolevulinic acid synthetase, the enzyme which

limits the rate of the porphyrin/heme biosynthetic pathway. The exact mechanism by which hematin produces symptomatic improvement in patients with acute episodes of the hepatic porphyrias has not been elucidated.<sup>1,9</sup>

Following intravenous administration of hematin in non-jaundiced human patients, an increase in fecal urobilinogen can be observed which is roughly proportional to the amount of hematin administered. This suggests an enterohepatic pathway as at least one route of elimination. Bilirubin metabolites are also excreted in the urine following hematin injections.<sup>2</sup>

PANHEMATIN (hemin for injection) therapy for the acute porphyrias is not curative. After discontinuation of PANHEMATIN treatment, symptoms generally return although in some cases remission is prolonged. Some neurological symptoms have improved weeks to months after therapy although little or no response was noted at the time of treatment.

Other aspects of human pharmacokinetics have not been defined.

## **INDICATIONS AND USAGE**

PANHEMATIN (hemin for injection) is indicated for the amelioration of recurrent attacks of acute intermittent porphyria temporally related to the menstrual cycle in susceptible women.

Manifestations such as pain, hypertension, tachycardia, abnormal mental status and mild to progressive neurologic signs may be controlled in selected patients with this disorder.

Similar findings have been reported in other patients with acute intermittent porphyria, porphyria variegata and hereditary coproporphyria. PANHEMATIN is not indicated in porphyria cutanea tarda.

## **CONTRAINDICATIONS**

PANHEMATIN is contraindicated in patients with known hypersensitivity to this drug.

## **WARNINGS**

**PANHEMATIN is made from human blood. Products made from human blood may contain infectious agents, such as viruses, that can cause disease. The risk that such products will transmit an infectious agent has been reduced by screening blood donors for prior exposure to certain viruses, by testing for the presence of certain current virus infections, and by inactivating certain**

**viruses. Despite these measures, such products can still potentially transmit disease. There is also the possibility that unknown infectious agents may be present in such products. ALL infections thought by a physician possibly to have been transmitted by this product should be reported by the physician or other healthcare provider to Lundbeck Inc., (1-800-455-1141). The physician should discuss the risks and benefits of this product with the patient.**

Because this product is made from human blood, it may carry a risk of transmitting infectious agents, e.g., viruses, and theoretically, the Creutzfeldt-Jakob disease (CJD) agent.

PANHEMATIN therapy is intended to limit the rate of porphyria/heme biosynthesis possibly by inhibiting the enzyme  $\delta$ -aminolevulinic acid synthetase. For this reason, drugs such as estrogens, barbituric acid derivatives and steroid metabolites which increase the activity of  $\delta$ -aminolevulinic acid synthetase should be avoided.

Also, because hemin for injection has exhibited transient, mild anticoagulant effects during clinical studies, concurrent anticoagulant therapy should be avoided.<sup>9</sup> The extent and duration of the hypocoagulable state induced by PANHEMATIN has not been established.

## **PRECAUTIONS**

### **General**

Clinical benefit from PANHEMATIN depends on prompt administration. Attacks of porphyria may progress to a point where irreversible neuronal damage has occurred. PANHEMATIN therapy is intended to prevent an attack from reaching the critical stage of neuronal degeneration. PANHEMATIN is not effective in repairing neuronal damage.<sup>9</sup>

Recommended dosage guidelines should be strictly followed. Reversible renal shutdown has been observed in a case where an excessive hematin dose (12.2 mg/kg) was administered in a single infusion. Oliguria and increased nitrogen retention occurred although the patient remained asymptomatic.<sup>4</sup> No worsening of renal function has been seen with administration of recommended dosages of hematin.<sup>9</sup>

A large arm vein or a central venous catheter should be utilized for the administration of PANHEMATIN to avoid the possibility of phlebitis.

Since reconstituted PANHEMATIN is not transparent, any undissolved particulate matter is difficult to see when inspected visually. Therefore, terminal filtration through a sterile 0.45 micron or smaller filter is recommended.

### **Tests for Diagnosis and Monitoring of Therapy**

Before PANHEMATIN therapy is begun, the presence of acute porphyria must be diagnosed using the following criteria:<sup>9</sup>

- a. Presence of clinical symptoms.
- b. Positive Watson-Schwartz or Hoesch test. (A negative Watson-Schwartz or Hoesch test indicates a porphyric attack is highly unlikely. When in doubt quantitative measures of  $\delta$ -aminolevulinic acid and porphobilinogen in serum or urine may aid in diagnosis.)

Urinary concentrations of the following compounds may be *monitored* during PANHEMATIN therapy. Drug effect will be demonstrated by a decrease in one or more of the following compounds.<sup>3-6</sup>

ALA –  $\delta$ -aminolevulinic acid

UPG – uroporphyrinogen

PBG – porphobilinogen

    coproporphyrin

### **Carcinogenesis, Mutagenesis, Impairment of Fertility**

No data are available on potential for carcinogenicity, mutagenicity or impairment of fertility in animals or humans.

### **Pregnancy**

*Teratogenic effects-Pregnancy Category C:* Animal reproduction studies have not been conducted with hematin. It is also not known whether hematin can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. For this reason PANHEMATIN should not be given to a pregnant woman unless the expected benefits are sufficiently important to the health and welfare of the patient to outweigh the unknown hazard to the fetus.

### **Nursing Mothers**

It is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when PANHEMATIN is administered to a nursing woman.

### **Pediatric Use**

Safety and effectiveness in pediatric patients under 16 years of age have not been established.

### **Geriatric Use**

Clinical studies in PANHEMATIN did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. Other reported clinical experience has not identified differences in response between the elderly and younger patients. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy.

## ADVERSE REACTIONS

Reversible renal shutdown has occurred with administration of excessive doses (See "PRECAUTIONS" section).

Phlebitis with or without leucocytosis and with or without mild pyrexia has occurred after administration of hematin through small arm veins.

There have been post-marketing and literature reports of thrombocytopenia and coagulopathy (including prolonged prothrombin time and prolonged partial thromboplastin time) in patients receiving PANHEMATIN. The initial literature report<sup>8</sup> described coagulopathy occurring in a patient receiving hematin therapy. This patient exhibited prolonged prothrombin time and partial thromboplastin time, thrombocytopenia, mild hypofibrinogenemia, mild elevation of fibrin split products, and a 10% fall in hematocrit.

**To report SUSPECTED ADVERSE REACTIONS, contact Lundbeck Inc. at 1-800-455-1141 or FDA at 1-800-FDA-1088 or [www.fda.gov/medwatch](http://www.fda.gov/medwatch).**

## OVERDOSAGE

Reversible renal shutdown has been observed in a case where an excessive hematin dose (12.2 mg/kg) was administered in a single infusion. Treatment of this case consisted of ethacrynic acid and mannitol.<sup>7</sup>

## DOSAGE AND ADMINISTRATION

Before administering PANHEMATIN, an appropriate period of alternate therapy (i.e., 400 g glucose/day for 1 to 2 days) must be considered. If improvement is unsatisfactory for the treatment of acute attacks of porphyria, an intravenous infusion of PANHEMATIN containing a dose of 1 to 4 mg/kg/day of hematin should be given over a period of 10 to 15 minutes for 3 to 14 days based on the clinical signs. In more severe cases this dose may be repeated no earlier than every 12 hours. No more than 6 mg/kg of hematin should be given in any 24 hour period.

After reconstitution each mL of PANHEMATIN contains the equivalent of approximately 7 mg of hematin. The drug may be administered directly from the vial.

### Dosage Calculation Table

---

1 mg hematin equivalent = 0.14 mL PANHEMATIN
2 mg hematin equivalent = 0.28 mL PANHEMATIN
3 mg hematin equivalent = 0.42 mL PANHEMATIN
4 mg hematin equivalent = 0.56 mL PANHEMATIN

Since reconstituted PANHEMATIN is not transparent, any undissolved particulate matter is difficult to see when inspected visually. Therefore, terminal filtration through a sterile 0.45 micron or smaller filter is recommended.

#### **Preparation of Solution:**

Reconstitute PANHEMATIN by aseptically adding 43 mL of Sterile Water for Injection, USP, to the dispensing vial. Immediately after adding diluent, the product should be shaken well for a period of 2 to 3 minutes to aid dissolution. **NOTE: Because PANHEMATIN contains no preservative and because PANHEMATIN undergoes rapid chemical decomposition in solution, it should not be reconstituted until immediately before use. After the first withdrawal from the vial, any solution remaining must be discarded.**

No drug or chemical agent should be added to a PANHEMATIN fluid admixture unless its effect on the chemical and physical stability has first been determined.

#### **HOW SUPPLIED**

PANHEMATIN is supplied as a sterile, lyophilized black powder in single dose dispensing vials (NDC 67386-701-54). When mixed as directed with Sterile Water for Injection, USP, each 43 mL provides the equivalent of approximately 301 mg hematin (7 mg/mL). Store lyophilized powder in refrigerator at 2-8°C (36-46°F) until time of use.

Caution: The packaging (vial stopper) of this product contains natural rubber latex which may cause allergic reactions.

#### **REFERENCES**

1. Bickers, D., Treatment of the Porphyrias: Mechanisms of Action, *J Invest Dermatol* 77(1):107-113, 1981.
2. Watson, C. J., Hematin and Porphyria, editorial, *N Engl J Med* 293(12):605-607, September 18, 1975.
3. Lamon, J. M., Hematin Therapy for Acute Porphyria, *Medicine* 58(3):252-269, 1979.
4. Dhar, G J., et al., Effects of Hematin in Hepatic Porphyria, *Ann Intern Med* 83:20-30, 1975.
5. Watson, C. J., et al., Use of Hematin in the Acute Attack of the "Inducible" Hepatic Porphyrias, *Adv Intern Med* 23:265-286, 1978.
6. McColl, K. E., et al., Treatment with Haematin in Acute Hepatic Porphyria, *Q J Med, New Series L* (198):161-174, Spring, 1981.
7. Dhar, G. J., et al., Transitory Renal Failure Following Rapid Administration of a Relatively Large Amount of Hematin in a Patient with Acute Intermittent Porphyria in Clinical Remission, *Acta Med Scand* 203:437-443, 1978.

8. Morris, D.L., et al., Coagulopathy Associated with Hematin Treatment for Acute Intermittent Porphyria, *Ann Intern Med* 95:700-701, 1981.
9. Pierach, C. A., Hematin Therapy for the Porphyric Attack, *Semin Liver Dis* 2(2):125-131, May, 1982.

Manufactured by: Catalent Pharma Solutions, LLC, Raleigh, NC 27616, U.S.A.

For: Lundbeck Inc., Deerfield, IL 60015, U.S.A.  
U.S. Lic. No. 1822



® Trademark of Lundbeck Inc.

Revised: February 2010